Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib with Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant HER2+ Breast Cancer
NCT04917900Phase 2Unknown
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by West China Hospital of Sichuan University. Primary endpoint: Pathological Complete Response Rate up to 2.5 years. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04917900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04917900.